Dr. Petrossian earned his MBA from the UCLA Anderson School of Management in 2014 and earned his Ph.D. & MS in Biomolecular Nanotechnology & Solid-State Device Physics as an NSF IGERT fellow at Arizona State University in 2007. He also holds a double B.S. in Electrical Engineering & Biomedical Engineering from California State University, Long Beach.

Prior to Candid, Andy was the Vice President Customer Experience and Planning at Scotts Miracle-Gro. Over 13 years there he held various leadership roles in sales, operations, strategy and supply chain. Prior to that time, Andy was a First Officer for Northwest Airlink. He served 8 years in the US Navy aboard the USS Enterprise and as a part of the Blue Angels Flight Demonstration Squadron. Andy graduated from Embry-Riddle Aeronautical University.

With over 35-years of experience in healthcare leadership, Javad has extensive experience in overall operations (product development,manufacturing and QA/RA) on a global scale, including North America, Europe, Latin America, and Asia.

Javad has held executive roles at Gambro , Toshiba Medical Systems, Bayer Healthcare, Siemens Healthcare, and NovaSignal and Nile.ai.

Javad’s business-oriented approach extends to product development and operational excellence. He has been instrumental in streamlining processes, reducing product costs, and implementing efficient organizational designs. His leadership has been crucial in driving product development strategies that align with regulatory compliance and market needs.

Michael Levitz is a strategic, execution-driven Chief Financial Officer with more than 20 years of public- company medical device experience, including over a decade as CFO leading global, high-growth organizations. Recognized for driving enterprise value, operational excellence, and investor confidence at companies such as Insulet Corporation in diabetes care, Michael combines financial acumen with strategic vision. As a trusted advisor and values-based leader, Michael brings deep experience in finance, corporate governance and organizational performance, along with a passion for advancing medical innovation and empowering high-impact teams. In addition to serving on the board and as chairman of the audit committee of Kandu Inc., Michael is president of PTP Advisory LLC and serves on the advisory board of Thirdwayv Inc. Michael began his career in the high-technology audit practice of Arthur Andersen, is a certified public accountant, and has a degree in business economics with emphasis in accounting from the University of California at Santa Barbara.

His work has earned him recognition as a pioneer in applied neuroscience and he has over 1800 patents filed with the US Patent and Trademark Office for various medical devices and brain-computer interface technologies. In addition to his academic and research achievements. He is also a successful entrepreneur, having founded eight startup companies. He is an Emmy Award-winning playwright and the author of two fiction novels.

Lisa Garrett joined Neurolutions in March 2023 and brings over 20 years experience in medical technology companies. Most recently Lisa was the CFO at Cardiva Medical until its acquisition by Haemonetics in 2021. Previously she served as CFO at ForSight Vision5, Inc., a pharmaceutical research company subsequently acquired by Allergan. Prior to ForSight Vision5, Lisa was the CFO at Corventis, Inc., a wearable arrhythmia sensor company acquired by Medtronic in 2014. Lisa also served in various financial roles at Guidant Corporation, Sybase and Eli Lilly. Lisa currently sits on the board of Channel Medsystems, a medical device company focused on women’s health. Lisa earned a B.B.S. in Accounting and an M.B.A from Indiana University.

Fred Khosravi is a Silicon Valley medical device entrepreneur with over 30 years of experience in medical technology, including management and executive positions in both large and small enterprises. He has co-founded Incept LLC and serves as its managing director, focusing on technology innovation and entrepreneurship in the life-sciences field and occasionally extending to information technology. Fred is credited as an inventor or co-inventor on over 200 patents and patent applications globally, holds degrees in mechanical engineering from Tennessee Tech University, and is involved in various organizations such as the Center for Strategic and International Studies, Spirit of America, and Technology for America.

William Tai is a successful entrepreneur and investor with over 30 years of experience in the technology industry. He is the Founder and Managing Partner of Amed Ventures, a San Francisco Bay Area-based venture capital fund focused on Medical Device and Medical Technologies investments. He is also the former VP of Business Development at CTBC Bank Corp. William has earned a Bachelor’s Degree in Finance from National Chengchi University and an MBA from Baruch College.

Kevin Reilly joined Ally Bridge Group in 2021 and is a Managing Director, Head of Medtech, for the private equity strategy, focused on transactions across healthcare subsectors. Before joining Ally Bridge Group, Kevin was a Principal at CRG, a healthcare investment management firm providing growth capital to companies through the form of long-term debt and equity. Kevin began his career in the Healthcare Investment Banking Group at Stifel. Kevin holds a B.S. in Finance and Information Systems from the University of Maryland.

Bret Christensen is a seasoned leader recognized for his exceptional ability to launch innovative solutions, penetrate markets and effectively scale businesses. With over two decades of experience in the healthcare sector, a specialized focus on women’s health and a comprehensive understanding of the broader healthcare landscape, Bret has consistently proven his ability to elevate emerging solutions into market share leaders, solidifying his reputation as a catalyst for growth and success.

Over the course of his distinguished career, Bret has held strategic commercial and general management leadership roles at Hologic (NASDAQ: HOLX), Myriad Genetics (NASDAQ: MYGN) and Insulet (NASDAQ: PODD), where he played a central role in revolutionizing treatments in women’s health care, oncology and diabetes, respectively. His strategic leadership drove significant revenue growth, achieved product commercialization success and advanced groundbreaking therapies that have redefined standards of care.

Bret’s expertise spans diagnostics, therapeutics and medical devices, positioning him as the ideal leader to accelerate Biote to its next level of growth. With a rare blend of business acumen and deep industry insight, he is uniquely equipped to drive Biote’s continued success as a leading educator in hormone optimization and therapeutic wellness while expanding its market presence and reach.

Bret holds a Bachelor of Science from Utah Valley University, a Masters of Business Administration from the University of Utah, David Eccles School of Business and several executive certifications from the University of Chicago Booth School of Business.

Calvin Portley has extensive work experience in various roles and industries with much of his time spent in healthcare technology commercialization. Calvin is the Chief Business Officer at Neurolutions, a position he has held since May 2020. Prior to that, he worked as a Venture Partner at Dangerous Ventures and the Managing Partner at Avon Growth Management, a lower middle market acquisition firm. Before that, he worked in various marketing and sales leadership positions at Doctor On Demand, Beckman Coulter, Johnson & Johnson, Alcon (a Novartis company), and The Kraft Heinz Company.
Calvin Portley completed his Master of Business Administration (M.B.A.) degree from the UCLA Anderson School of Management in 2014 and obtained his Bachelor of Business Administration (B.B.A) in Marketing from The University of Texas at Arlington in 2003.

Amarpreet Sawhney is the President and CEO of Ocular Therapeutix, a company that specializes in ophthalmic surgical wound management and drug delivery. Before that, he founded and led Confluent Surgical, a biosurgery company that was acquired by Covidien. He was also the Chairman of MarketRx, a pharmaceutical marketing and sales analytics provider that was acquired by Cognizant. Dr. Sawhney has founded and is a member of the board of several companies, including Ostial Corp., TiE Boston, Ocular Therapeutix, Augmenix, and Incept LLC. He has also received numerous awards, including the MassDevice “Five Most Innovative Medical Device CEOs” award and the MIT Global Indus Technovators Award. Dr. Sawhney has a Ph.D. and M.S. in Chemical Engineering from the University of Texas at Austin and a B.Tech. in Chemical Engineering from IIT Delhi.